… NEWYORK, NY— As part of its ongoing efforts to do whatever it takes to speed delivery of transformative … shares the risk of drug development, thus helping to speed companies’ abilities to reach critical decision points for … process toward clinical trials and patients, competitive pressures and tough allocation decisions too often get in …

… testing that she carried a LRRK2 variant — one of the most common genetic contributors to Parkinson’s that is … the biology of Parkinson’s through in-person clinic visits, scans and biosample collection. As a part of PPMI, … open to anyone age 18 or older with or without Parkinson’s, where participants contribute through regular surveys and …

… aggregation of a protein known as alpha-synuclein appears to play a critical role in Parkinson's disease. This project … ability to thwart alpha-synuclein aggregation . If these preliminary tests are promising, future work could explore … slow or halt disease progression.   Anticipated Outcome:           This project represents an important first …

… and trigeminal neuralgia offers efficacy and safety that compare favorably with other treatment options, investigators reported here. Radiosurgery led to substantial … cranial nerve V entry root zone into the brain stem. The prescribed radiation dose ranged from 70 to 90 Gy …

… The most common question I receive from our community is: "How close are we to achieving our goal?" It is perhaps the hardest question … clinical trials, contributing data through online portals and wearables, advocating for public policy that …

… HLA and KIR. The central element of this project is to apply next generation sequencing methods and a validated … management of many of these diseases, we are still missing complete and coherent models of pathogenesis and as a … the same variants show association with multiple traits, whereas in other cases, the associations are mediated by …